Basket cover image
15 handpicked stocks

Modern Vices

Explore companies transforming how we play, bet, and engage online. These carefully selected stocks represent leaders in digital entertainment and betting platforms poised to capture growing consumer demand for tech-driven leisure experiences.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juin 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

DKNG

DraftKings

DKNG

Current price

$45.02

As a leader in digital sports entertainment, the company is at the forefront of the online sports betting and daily fantasy sports markets.

PENN

Penn Entertainment Inc

PENN

Current price

$18.52

This company merges traditional casino gaming with modern online sports betting through its significant media and digital partnerships.

CZR

Caesars Entertainment Inc.

CZR

Current price

$25.28

This legacy casino and entertainment giant has aggressively expanded into the digital space with online casino and sports wagering applications.

About This Group of Stocks

1

Our Expert Thinking

These companies leverage technology to serve modern entertainment needs through online sports betting, gaming, and digital media. As leisure activities increasingly shift to digital platforms, these market leaders are positioned to benefit from expanding regulatory approval and growing user engagement.

2

What You Need to Know

This collection represents an aggressive growth component for your portfolio, targeting sectors with high user engagement and expanding market reach. A significant current catalyst is the ongoing legalization of online sports betting in new global markets, unlocking substantial revenue potential.

3

Why These Stocks

We've selected dominant players and key innovators within the digital entertainment landscape. These companies are at the forefront of transforming traditional leisure activities into technology-driven experiences, with established platforms and emerging leaders poised for significant growth.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+53.15%

Group Performance Snapshot

53.15%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 53.15% over the next year.

10 of 13

Stocks Rated Buy by Analysts

10 of 13 assets in this group are rated Buy by professional analysts.

0.5%

Group Growth

This group averaged a 0.5% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🎮

The Digital Entertainment Revolution

Traditional vices are being transformed by technology, creating massive new markets. These companies are capturing billions in consumer spending that's rapidly shifting from physical venues to digital platforms.

📱

Regulatory Tailwinds

As more states and countries legalize online betting and gaming, these companies are positioned to enter massive untapped markets. Early movers with established platforms stand to gain significant market share.

💰

High User Engagement Means Big Money

These platforms excel at keeping users active and spending. With sophisticated monetization strategies and growing user bases, they're building revenue models that could deliver impressive long-term growth.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Orphan Drug Moats: Leaders In Rare Disease

Orphan Drug Moats: Leaders In Rare Disease

The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.

View stocks
Nvidia's China Chip Pivot

Nvidia's China Chip Pivot

Nvidia is developing a new, compliant AI chip for China, aiming to recapture market share lost to U.S. export controls. This strategic pivot creates a ripple effect, potentially benefiting the entire semiconductor supply chain that supports the production and deployment of this advanced hardware.

View stocks
Navigating The Autonomous Driving Shakeout

Navigating The Autonomous Driving Shakeout

A class-action lawsuit against Tesla regarding its Full Self-Driving claims puts the company's marketing and technology under intense scrutiny. This legal challenge could boost demand for competing autonomous driving technologies, creating opportunities for companies that supply advanced sensors and software.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.